Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern
Katharina S. Schmitz, Daryl Geers, Rory D. de Vries, Tiziana Francesca Bovier, Anna Z. Mykytyn, Corine H. GeurtsvanKessel, Bart L. Haagmans, Matteo Porotto, Rik L. de Swart, Anne Moscona
Abstract
SARS-CoV-2, the causative agent of COVID-19, continues to spread globally, with waves resulting from new variants that evade immunity generated by vaccines and previous strains and escape available monoclonal antibody therapy. Fusion-inhibitory peptides may provide an intervention strategy that is not similarly affected by this viral evolution.
Topics & Concepts
PotencyVirologyChemistryInhibitory postsynaptic potentialSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)PharmacologyMicrobiologyBiologyMedicineIn vitroBiochemistryDiseaseInfectious disease (medical specialty)PathologyNeuroscienceSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesPharmacological Receptor Mechanisms and Effects